Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Myelodysplastic Syndromes 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma 4Leukemia 4Leukemia, Myeloid, Acute 3Hematologic Neoplasms 3Lymphoma, Non-Hodgkin 2Immunoproliferative Disorders 2Immune System Diseases 2Cytokine Release Syndrome 2Triple Negative Breast Neoplasms 1Primary Immunodeficiency Diseases 1Osteopetrosis 1Neurotoxicity Syndromes 1Neoplasm, Residual 1Multiple Myeloma 1Lymphoproliferative Disorders 1Lymphoma, B-Cell 1Lymphohistiocytosis, Hemophagocytic 1Lymphatic Diseases 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Graft vs Host Disease 1Epstein-Barr Virus Infections 1Cytopenia 1Breast Neoplasms 1Anemia, Refractory, with Excess of Blasts 1Anemia, Aplastic 1

Interventions

fludarabine phosphate 4Cyclophosphamide 4blinatumomab 3Rituximab 3Lenalidomide 2Immunotherapy, Adoptive 2venetoclax 1trastuzumab deruxtecan 1tisagenlecleucel 1pembrolizumab 1obinutuzumab 1niraparib 1nilotinib 1isatuximab 1acalabrutinib 1Zymosan 1Whole-Body Irradiation 1Trastuzumab 1Sodium Chloride 1Sirolimus 1Radiotherapy 1Pentostatin 1NKTR-255 1Mycophenolic Acid 1Melphalan 1Magnetic Resonance Imaging 1Immunotherapy 1Imatinib Mesylate 1Histamine Antagonists 1Exercise Test 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Neoplasm, Residual × AP 1903 reagent × Clear all
NCT03459170 2022-07-12

Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant

Bellicum Pharmaceuticals

Phase 1 Active not recruiting
15 enrolled
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Neoplasm, Residual, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡